Advertisement

Topics

Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

13:01 EDT 14 Mar 2018 | BioPortfolio Report Blog

Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF Pipeline Review, H1 2018


Summary


Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF Connective tissue growth factor CTGF, also known as CCN2 is a matricellular protein of the CCN family of extracellular matrixassociated heparinbinding proteins.


CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis TGFbetadependent. This includes fibrosis of major organs, fibroproliferative diseases, and scarring. CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing.


Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.


The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Respiratory, Genetic Disorders, Oncology, Dermatology, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Fibrosis, Hypertrophic Scars, NonAlcoholic Steatohepatitis NASH, Acute Lung Injury, Age Related Macular Degeneration, Chronic Kidney Disease Chronic Renal Failure, Cirrhosis, Fatty Liver Disease, Keloids, Kidney Fibrosis, Liver Cancer, Metabolic Syndrome, Myocardial Fibrosis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Radiation Toxicity Radiation Sickness, Acute Radiation Syndrome, Scar, Systemic Sclerosis Scleroderma and Wet Neovascular / Exudative Macular Degeneration.


The latest report Connective Tissue Growth Factor Pipeline Review, H1 2018, outlays comprehensive information on the Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


It also reviews key players involved in Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF

The report reviews Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics and enlists all their major and minor projects

The report assesses Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Connective Tissue Growth Factor CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...